NCT05419362 - GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Gastric CancerGastroesophageal Junction Adenocarcinoma

Interventions

DRUG

GEN-001

The capsules taken by mouth once a daily. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)

DRUG

Avelumab

800 mg given by intravenous (IV) infusion once every 2 weeks

Trial Locations (5)

Ajou University Hospital, Gyeonggi-do

Seoul National University Bundang Hospital, Gyeonggi-do

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Yonsei University Health System, Severance Hospital, Seoul